Popular Trials
Virus Therapy
LBP-EC01 for Urinary Tract Infection
Recruiting0 awardsPhase 2
Anniston, Alabama
This trial is testing LBP-EC01, a virus mixture that targets E. coli bacteria, in patients with recurring UTIs caused by E. coli. The study aims to find the best dose and compare its effectiveness and safety with standard antibiotic treatment.
Procedure
DNA PCR vs Urine Culture for Urinary Tract Infection
Recruiting1 award1 criteria
Cleveland, Ohio
This trial is looking at adults with UTI symptoms. Participants will be randomly assigned to two different groups. They will fill out questionnaires at the start and end of the study. If they are given
Immunomodulatory Agent
Rituximab + Lenalidomide + Ibrutinib for Follicular Lymphoma
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is testing the side effects and best dose of two drugs, lenalidomide and ibrutinib, when given with a third drug, rituximab, to treat patients with follicular lymphoma that has not been treated before.
Popular Filters
Trials for Chronic Lymphocytic Leukemia Patients
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
Recruiting2 awardsPhase 3
Lebanon, New Hampshire
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Anti-metabolites
Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib +/− Rituximab for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Houston, Texas
This trial is studying ibrutinib with or without rituximab to see which is more effective in treating patients with chronic lymphocytic leukemia that has come back after treatment.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Trials for CLL Patients
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
Recruiting2 awardsPhase 3
Lebanon, New Hampshire
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Anti-metabolites
Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib +/− Rituximab for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Houston, Texas
This trial is studying ibrutinib with or without rituximab to see which is more effective in treating patients with chronic lymphocytic leukemia that has come back after treatment.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Trials for CD20 Positive Patients
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Kinase Inhibitor
Ibrutinib + Rituximab for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing ibrutinib and rituximab as a treatment for mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them.
Immunomodulatory Agent
Triple Therapy for CLL/SLL
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Rituximab for Follicular Lymphoma
Recruiting2 awardsPhase 3
Mobile, Alabama
This trial will compare ibrutinib + rituximab vs rituximab alone in people with untreated follicular lymphoma. The goal is to see if ibrutinib helps people live longer without the cancer progressing.
Phase 3 Trials
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
Recruiting2 awardsPhase 3
Lebanon, New Hampshire
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Anti-metabolites
Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib + Stem Cell Transplant for Lymphoma
Recruiting1 awardPhase 3
Anchorage, Alaska
This trial is studying whether adding ibrutinib to chemotherapy before and after stem cell transplant helps the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.
Trials With No Placebo
Behavioral Intervention
Discharge Antibiotic Stewardship for Pediatric Infections
Recruiting1 award3 criteria
Saint Louis, Missouri
This trial tests if a discharge stewardship bundle can reduce inappropriate antibiotic prescribing for kids with 3 common infections. It will involve surveys, interviews and feedback reports.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.